US20050112200A1 - EDTA containing compositions and uses thereof - Google Patents
EDTA containing compositions and uses thereof Download PDFInfo
- Publication number
- US20050112200A1 US20050112200A1 US10/939,737 US93973704A US2005112200A1 US 20050112200 A1 US20050112200 A1 US 20050112200A1 US 93973704 A US93973704 A US 93973704A US 2005112200 A1 US2005112200 A1 US 2005112200A1
- Authority
- US
- United States
- Prior art keywords
- edta
- patient
- composition
- atherosclerosis
- therapeutic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 title claims abstract description 78
- 239000000203 mixture Substances 0.000 title claims abstract description 72
- 238000000034 method Methods 0.000 claims abstract description 49
- 201000001320 Atherosclerosis Diseases 0.000 claims abstract description 33
- 238000011282 treatment Methods 0.000 claims abstract description 19
- 229910001385 heavy metal Inorganic materials 0.000 claims abstract description 14
- 238000009825 accumulation Methods 0.000 claims abstract description 13
- 230000002265 prevention Effects 0.000 claims abstract description 5
- 229910052791 calcium Inorganic materials 0.000 claims description 30
- 239000011575 calcium Substances 0.000 claims description 30
- 239000003814 drug Substances 0.000 claims description 30
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 29
- MXXWOMGUGJBKIW-YPCIICBESA-N piperine Chemical compound C=1C=C2OCOC2=CC=1/C=C/C=C/C(=O)N1CCCCC1 MXXWOMGUGJBKIW-YPCIICBESA-N 0.000 claims description 26
- 229940075559 piperine Drugs 0.000 claims description 26
- WVWHRXVVAYXKDE-UHFFFAOYSA-N piperine Natural products O=C(C=CC=Cc1ccc2OCOc2c1)C3CCCCN3 WVWHRXVVAYXKDE-UHFFFAOYSA-N 0.000 claims description 26
- 235000019100 piperine Nutrition 0.000 claims description 26
- 229940124597 therapeutic agent Drugs 0.000 claims description 20
- 229940002612 prodrug Drugs 0.000 claims description 19
- 239000000651 prodrug Substances 0.000 claims description 19
- 229940127291 Calcium channel antagonist Drugs 0.000 claims description 10
- 239000002876 beta blocker Substances 0.000 claims description 10
- 239000000480 calcium channel blocker Substances 0.000 claims description 10
- 239000005541 ACE inhibitor Substances 0.000 claims description 9
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims description 9
- 229940097320 beta blocking agent Drugs 0.000 claims description 9
- 239000002934 diuretic Substances 0.000 claims description 9
- 230000001882 diuretic effect Effects 0.000 claims description 9
- 239000003937 drug carrier Substances 0.000 claims description 8
- 238000009505 enteric coating Methods 0.000 claims description 8
- 239000002702 enteric coating Substances 0.000 claims description 8
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 4
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims description 2
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims description 2
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims description 2
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims description 2
- 229960001484 edetic acid Drugs 0.000 description 64
- 150000001875 compounds Chemical class 0.000 description 36
- 208000029078 coronary artery disease Diseases 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- -1 cyclohexyl EDTA Chemical compound 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 7
- 229910052751 metal Inorganic materials 0.000 description 7
- 239000002184 metal Substances 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 6
- 210000001367 artery Anatomy 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 210000004351 coronary vessel Anatomy 0.000 description 6
- 150000002739 metals Chemical class 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 206010002383 Angina Pectoris Diseases 0.000 description 3
- 206010008479 Chest Pain Diseases 0.000 description 3
- 229920000858 Cyclodextrin Polymers 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 238000010894 electron beam technology Methods 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000008177 pharmaceutical agent Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 201000000057 Coronary Stenosis Diseases 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000009056 active transport Effects 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000036983 biotransformation Effects 0.000 description 2
- 230000036765 blood level Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 208000026758 coronary atherosclerosis Diseases 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000004324 lymphatic system Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000005956 quaternization reaction Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 208000013220 shortness of breath Diseases 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000003325 tomography Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 1
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- 229920003139 Eudragit® L 100 Polymers 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 101710107035 Gamma-glutamyltranspeptidase Proteins 0.000 description 1
- 101710173228 Glutathione hydrolase proenzyme Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- GOEMGAFJFRBGGG-UHFFFAOYSA-N acebutolol Chemical compound CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(C(C)=O)=C1 GOEMGAFJFRBGGG-UHFFFAOYSA-N 0.000 description 1
- 229960002122 acebutolol Drugs 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 229940030611 beta-adrenergic blocking agent Drugs 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 150000001669 calcium Chemical class 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 1
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 1
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000009057 passive transport Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229940113116 polyethylene glycol 1000 Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 238000009117 preventive therapy Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
Definitions
- This invention relates to EDTA containing compositions and therapeutic uses thereof.
- Ethylenediamine tetra-acetic acid binds to metals, for example transition state metals, and is used therapeutically for the treatment of heavy metal accumulation.
- EDTA Ethylenediamine tetra-acetic acid
- Atherosclerosis is a process where cholesterol, calcium and other minerals accumulate on the inside lining of blood vessels and, over time, clog them. This process, which is often associated with aging, is often referred to as hardening of the arteries, atherosclerosis and arterial plaque buildup. Atherosclerosis contributes to and accounts for the high numbers of individuals suffering from cardiovascular disease in the United States and other developed countries. Examples of such diseases are angina (chest pain due to poor blood circulation to the heart), heart attack, peripheral vascular disease (poor circulation to the legs and feet), and stroke. These conditions can be both physically disabling and mentally taxing to the patients. Moreover cardiovascular disease is the leading cause of death in the U.S.
- EDTA can bind to metals deposited in the arterial wall and in plaques on the arterial walls of patients suffering from atherosclerosis.
- Intravenous EDTA is administered by some “complementary” physicians on an outpatient basis to treat atherosclerosis.
- the intravenous administration of EDTA is time consuming and expensive.
- a preferable method of treatment is one where the patient can administer the treatment himself, e.g. orally. While oral EDTA is available, its effectiveness has been limited by its poor absorption bioavailability.
- This invention is based in part on the use of agents in combination with EDTA that can improve the bioavailability, absorption, and/or half-life of EDTA in the body, thus improving the chances of successful oral administration of EDTA.
- compositions are useful in therapeutic applications, including modulation of disease or disease symptoms in a patient.
- compositions are useful as metal chelators through their ability to bind metals, (e.g., transition state metals).
- an orally available composition including piperine and EDTA or a pharmaceutically acceptable derivative or pro-drug thereof is provided.
- the composition also includes a pharmaceutical carrier or an additional therapeutic agent such as an ACE inhibitor, a calcium channel blocker, a beta-blocker, or a diuretic.
- an orally available composition including piperine and EDTA is provided.
- an orally available composition including enteric coated EDTA or a pharmaceutically acceptable derivative or pro-drug thereof is provided.
- the enteric coating can include cellulose acetate phthalate or hydroxypropylmethylcellulose phthalate.
- the composition can also include a pharmaceutical carrier or an additional therapeutic agent such as an ACE inhibitor, a calcium channel blocker, a beta-blocker, or a diuretic.
- the additional therupeutic agent is a statin.
- the composition can also include piperine.
- an orally available composition including enteric coated EDTA is provided.
- the composition can also include piperine.
- a method for the treatment or prevention of atherosclerosis includes identifying a patient having atherosclerosis or at risk of having atherosclerosis, and orally administering to the patient a composition including EDTA or a pharmaceutically acceptable prodrug or derivative thereof and piperine.
- the EDTA is enteric coated.
- the method also includes administering to the patient an additional therapeutic agent such as an ACE inhibitor, a calcium channel blocker, a beta-blocker, or a diuretic.
- the patient can be identified as having atherosclerosis or being at risk of having atherosclerosis using a calcium score (a measurement obtained by performing an ultrafast electron beam CT scan of the coronary arteries). In some instances the method may also reduce the calcium score.
- a method of the treatment or prevention of atherosclerosis includes identifying a patient having atherosclerosis or at risk for having atherosclerosis, and orally administering to the patient a composition including enteric coated EDTA or a pharmaceutically acceptable prodrug or derivative thereof.
- the composition also includes piperine.
- the method also includes administering to the patient an additional therapeutic agent such as an ACE inhibitor, a calcium channel blocker, a beta-blocker, or a diuretic.
- the patient can be identified as having atherosclerosis or being at risk of having atherosclerosis using a calcium score. In some instances, the method may reduce the calcium score of the patient.
- Another aspect of the invention includes a method for the treatment of heavy metal accumulation.
- the method includes identifying a patient having heavy metal accumulation, and orally administering to the patient a composition comprising EDTA or a pharmaceutically acceptable prodrug or derivative thereof and piperine.
- the composition can be enteric coated.
- the composition can also be administered together with an additional therapeutic agent.
- Another aspect of the invention includes a method of the treatment heavy metal accumulation, where the method includes identifying a patient having heavy metal accumulation, and orally administering to the patient a composition comprising enteric coated EDTA or a pharmaceutically acceptable prodrug or derivative thereof.
- the composition also includes piperine.
- the method also includes administering to the patient an additional therapeutic agent.
- a patient can administer EDTA compositions orally, and need not have them administered intravenously. Accordingly, a patient need not be admitted into a medical facility for treatment, which results in significantly lower costs of administration.
- the compositions disclosed herein require less frequent administration than traditional orally administered EDTA.
- the EDTA is of a time release formulation, a patient can take higher dosages, as each dose is released in a controlled manner into the blood stream.
- EDTA binds to metals in the body. Described below are techniques used in the use and preparation of orally available EDTA compositions in patients having atherosclerosis or heavy metal accumulation.
- the invention also relates to compositions including EDTA related compounds such as cyclohexyl EDTA monoanhydride (CDTAMA) as described in U.S. Pat. No. 5,021,571, or the EDTA related compounds described in U.S. Pat. No. 6,080,785 both of which are incorporated by reference in their entirety.
- CDTAMA cyclohexyl EDTA monoanhydride
- the efficacy of the administration of a composition described herein There are a variety of methods available to determine the efficacy of the administration of a composition described herein. If the EDTA containing composition is being used to treat heavy metal accumulation, the effectiveness of the composition can be determined, for example, using laboratory tests showing a decrease in amount of toxic heavy metals. On the other hand, if the EDTA containing composition is administered to a patient having coronary artery disease, the effectiveness of the compound can be determined, for example, by the patient's improved performance on a stress test, decrease in chest pain, or decrease in a patient's shortness of breath.
- a possible alternative to monitor the effectiveness of a therapeutic agent in treating coronary artery disease includes the use of coronary artery calcium as a marker for calcified plaque (calcified deposits of cholesterol and fat buildup) in a blood vessel. Plaque formation is also known as atherosclerosis.
- EBCT electron beam computerized tomography
- Coronary artery calcium often occurs years or decades before the development of heart disease symptoms such as chest pain or shortness of breath.
- Electron beam computerized tomography is a very sensitive method of detecting this calcium, and is therefore a good screening test for coronary atherosclerosis.
- the calcium score for each artery reflects the total amount of calcium in that specific artery of the heart.
- the total calcium score is equal to the total amount of coronary artery calcium in the heart.
- coronary artery calcium reflects the total amount of calcified plaque in the heart, the higher the calcium scores, the greater the amount of atherosclerosis in the heart.
- the calcium score does not correlate directly to the percentage narrowing of an artery, but it does correlate with the severity of the underlying coronary atherosclerosis (total plaque burden). However, the higher the calcium score in the heart, the greater the probability of a significant narrowing of arteries throughout the patient.
- the calcium score is used to determine the calcium percentile, which compares the patient's calcium score to that of other asymptomatic or symptomatic people of the same age and sex.
- the calcium score in combination with the calcium percentile, enables a physician to determine the risk to a patient of developing symptomatic coronary artery disease, and to measure the progression of disease and the effectiveness of treatment.
- Table 1 below provides an example of a correlation of calcium scores to risk of Coronary Artery Disease (CAD).
- One approach combines EDTA with a bioavailability enhancer such as piperine.
- the resulting composition can improve absorption of the EDTA into the bloodstream, relative to the administration of EDTA alone.
- the combination of piperine with EDTA and EDTA related compounds could result in a higher plasma concentration and a longer presence of the EDTA in the body, thus improving the effectiveness of the EDTA or related compound. Accordingly, this can allow a smaller dose to be used (correlating to the increased effectiveness).
- the decrease in dose can correlate with decreased side effects (i.e., reduced toxicity) of the EDTA.
- the effective bioenhancing dose of piperine for EDTA compounds can vary, however a dose of approximately 0.2-5% (wt/wt) (e.g., 0.25, 0.5, 1.0, 2.0, 4.0, 5.0% wt/wt or any range in between) of the active drug (e.g., EDTA) can be an appropriate bioenhancing dose of piperine to improve the bioavailability of the EDTA.
- a dose of approximately 0.2-5% (wt/wt) e.g., 0.25, 0.5, 1.0, 2.0, 4.0, 5.0% wt/wt or any range in between
- the active drug e.g., EDTA
- piperine may have in improving the bioavailability of EDTA and related compounds: a) non-specific mechanisms promoting rapid absorption of drugs and nutrients, e.g., increased blood supply to the gastrointestinal tract, decreased hydrochloric acid secretion which prevents breakdown of some drugs, increased emulsifying content of the gut, increased enzymes like gamma-glutamyl transpeptidase which participate in active and passive transport of nutrients to the intestinal cells, and b) non-specific mechanisms inhibiting enzymes participating in biotransformation of drugs, preventing their inactivation and elimination.
- the improved bioavailability with administration of piperine can be a result of both of the mechanisms, i.e., increased absorption from the gut and the slow down of biotransformation, inactivation and elimination from the system.
- the latter mechanism is probably the most important in sustaining the elevated blood levels of the EDTA, and making it more bioavailable to the tissue.
- a rapid absorption to the blood stream may account for increased blood levels of the EDTA, it is the inhibition of drug (i.e., EDTA) biotransforming enzymes with piperine that makes a drug stay in the body longer, in higher quantities, which makes it more effective.
- EDTA and/or related compounds can also have an enteric coating to prevent degradation of the compound in the stomach.
- An enteric coating does not dissolve in the acidic environment of the stomach, but rather dissolves in the alkaline environment of the small intestine. Accordingly, the drug (e.g., EDTA or a related compound) is able to pass through the stomach and is released from the small intestine, which provides improved bioavailability.
- Methods of enteric coating are known to those of skill in the art as seen for example in C. Signorino, “Aqueous Enteric Coating,” Pharm. Technol. Tableting & Granulation Yearbook 25-26 (1999) and M. P.
- EDTA is in a “time-release” formulation.
- a time release formulation provides a more even amount of active drug (e.g., EDTA) in the blood stream over a prolonged period of time, thus reducing or in some instances avoiding the frequent peaks and valleys of medication levels one can encounter using more traditional methods of oral administration. Accordingly, the patient is provided with a more stable therapeutic environment.
- Another advantage of the time release formulation is that it allows the patient to take dosages of the EDTA or EDTA related compound with less frequency than would be required with uncoated EDTA. Examples of time release formulations include cocoa butter, waxes, polymers, etc. Another example of a time release formulation is methylcellulose K 100 M USP. Formulations that release the desired compound over about 6 to about 8 hours are generally preferred.
- bioavailability refers to the degree and rate at which a substance (e.g., a drug) is absorbed into a living system or is made available at the site of physiological activity.
- diuretic refers to a substance, which increases the production and elimination of urine.
- beta-blocker refers to a pharmaceutical agent, such as propanolol, that opposes the excitatory effects of norepinephrine released from sympathetic nerve endings at beta-receptors and is used for the treatment of angina, hypertension, arrhythmia, and migraine. Also called beta-adrenergic blocking agent.
- ACE inhibitor refers to an antihypertensive drug that blocks the formation of angiotensin in the kidney, leading to relaxation of the arteries and promotes the excretion of salt and water by inhibiting the activity of the angiotensin converting enzyme.
- calcium channel blocker refers to a pharmaceutical agent that prevents or slows the influx of calcium ions into smooth muscle cells. Calcium channel blockers can be used, for example, to treat some forms of angina pectoris and some cardiac arrhythmias.
- statin refers to of pharmaceutical agent that acts by competitively inhibiting 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, an enzyme involved in the liver cholesterol synthesis.
- HMG CoA 3-hydroxy-3-methylglutaryl coenzyme A
- a “pharmaceutically acceptable derivative or prodrug” means any pharmaceutically acceptable salt, ester, salt of an ester, or other derivative of a compound of this invention, which, upon administration to a recipient, is capable of providing (directly or indirectly) a compound of this invention.
- Particularly favored derivatives and prodrugs are those that increase the bioavailability of the compounds of this invention when such compounds are administered to a mammal (e.g., by allowing an orally administered compound to be more readily absorbed into the blood) or which enhance delivery of the parent compound to a biological compartment (e.g., the brain or lymphatic system) relative to the parent species.
- Preferred prodrugs include derivatives where a group which enhances aqueous solubility or active transport through the gut membrane is appended to the structure of formulae described herein.
- the compounds of this invention may be modified by appending appropriate chemical functionalities (e.g., carboxylic acids, esters, amides, ethers, etc.) to enhance selective biological properties.
- appropriate chemical functionalities e.g., carboxylic acids, esters, amides, ethers, etc.
- modifications are known in the art and include those which increase biological penetration into a given biological compartment (e.g., blood, lymphatic system, central nervous system), increase oral availability, increase solubility to allow administration by injection, alter metabolism and alter rate of excretion.
- Pharmaceutically acceptable salts of the compounds of this invention include those derived from pharmaceutically acceptable inorganic and organic acids and bases.
- suitable acid salts include acetate, adipate, benzoate, benzenesulfonate, butyrate, citrate, digluconate, dodecylsulfate, formate, fumarate, glycolate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, lactate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, palmoate, phosphate, picrate, pivalate, propionate, salicylate, succinate, sulfate, tartrate, tosylate and undecanoate.
- Salts derived from appropriate bases include alkali metal (e.g., sodium), alkaline earth metal (e.g., magnesium), ammonium and N-(alkyl) 4 + salts.
- alkali metal e.g., sodium
- alkaline earth metal e.g., magnesium
- ammonium e.g., sodium
- N-(alkyl) 4 + salts e.g., sodium
- alkali metal e.g., sodium
- alkaline earth metal e.g., magnesium
- ammonium e.g., sodium
- N-(alkyl) 4 + salts e.g., sodium
- compositions of this invention will be administered from about 1 to about 6 times per day.
- Each dose i.e., administration
- Such administration can be used as a chronic, acute, or prophylactic therapy.
- the amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the patient treated.
- a typical preparation will contain from about 5% to about 95% active compound (wt/wt) Alternatively, such preparations contain from about 20% to about 80% active compound.
- the piperine is administered at about 0.2-5% (wt/wt) (e.g., 0.2-1.0, 1.0-2.5, or 2.5-5% wt/wt) relative to the EDTA or related compound.
- a maintenance dose of a composition of this invention can be administered, if necessary. Subsequently, the dosage or frequency of administration, or both, may be reduced, as a function of the symptoms, to a level at which the improved condition is retained. Patients may, however, require intermittent treatment on a long-term basis upon any recurrence of disease symptoms.
- compositions of this invention can include EDTA or a pharmaceutically acceptable derivative or prodrug thereof; an additional agent including for example, piperine, acebutolol, bisoprololm, captopril, enalapril, hydrochlorothiazide, etc; and any pharmaceutically acceptable carrier, adjuvant or vehicle.
- Alternate compositions of this invention include EDTA or a pharmaceutically acceptable derivative or prodrug thereof; and a pharmaceutically acceptable carrier, adjuvant or vehicle.
- the compositions delineated herein include EDTA and derivatives thereof, as well as additional therapeutic agents if present, in amounts effective for achieving a modulation of disease or disease symptoms, including atherosclerosis or symptoms thereof.
- pharmaceutically acceptable carrier or adjuvant refers to a carrier or adjuvant that may be administered to a patient, together with a compound of this invention, and which does not destroy the pharmacological activity thereof and is nontoxic when administered in doses sufficient to deliver a therapeutic amount of the compound.
- Pharmaceutically acceptable carriers, adjuvants and vehicles that may be used in the pharmaceutical compositions of this invention include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, self-emulsifying drug delivery systems (SEDDS) such as d- ⁇ -tocopherol polyethyleneglycol 1000 succinate, surfactants used in pharmaceutical dosage forms such as Tweens or other similar polymeric delivery matrices, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-
- compositions of this invention can be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, emulsions and aqueous suspensions, dispersions and solutions.
- carriers that are commonly used include lactose and corn starch.
- Lubricating agents such as magnesium stearate, are also typically added.
- useful diluents include lactose and dried corn starch.
- compositions of this invention include a combination of EDTA or a pharmaceutically acceptable prodrug or derivative thereof and one or more additional therapeutic or agents
- both the compound and the additional agent should be present at dosage levels of between about 1 to 100%, and e.g., between about 5 to 95% of the dosage normally administered in a monotherapy regimen.
- the additional agents may be administered separately, as part of a multiple dose regimen, from the compounds of this invention. Alternatively, those agents may be part of a single dosage form, mixed together with the compounds of this invention in a single composition.
- the compounds, compositions, and methods of combination therapy delineated herein are useful to treat atherosclerosis and related symptoms.
- the concept of “treating” or “treatment” refers to activity that prevents, alleviates, or ameliorates any primary phenomena or secondary symptoms associated with atherosclerosis or heavy metal accumulation.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Abstract
Description
- This application claims priority under 35 USC §119(e) to U.S. Patent Application Ser. No. 60/502,820, filed on Sep. 12, 2003, the entire contents of which are hereby incorporated by reference.
- This invention relates to EDTA containing compositions and therapeutic uses thereof.
- Ethylenediamine tetra-acetic acid (EDTA) binds to metals, for example transition state metals, and is used therapeutically for the treatment of heavy metal accumulation. However, another potential therapeutic use for EDTA is treatment of atherosclerosis.
- Atherosclerosis is a process where cholesterol, calcium and other minerals accumulate on the inside lining of blood vessels and, over time, clog them. This process, which is often associated with aging, is often referred to as hardening of the arteries, atherosclerosis and arterial plaque buildup. Atherosclerosis contributes to and accounts for the high numbers of individuals suffering from cardiovascular disease in the United States and other developed countries. Examples of such diseases are angina (chest pain due to poor blood circulation to the heart), heart attack, peripheral vascular disease (poor circulation to the legs and feet), and stroke. These conditions can be both physically disabling and mentally taxing to the patients. Moreover cardiovascular disease is the leading cause of death in the U.S.
- EDTA can bind to metals deposited in the arterial wall and in plaques on the arterial walls of patients suffering from atherosclerosis. Intravenous EDTA is administered by some “complementary” physicians on an outpatient basis to treat atherosclerosis. However, the intravenous administration of EDTA is time consuming and expensive. A preferable method of treatment is one where the patient can administer the treatment himself, e.g. orally. While oral EDTA is available, its effectiveness has been limited by its poor absorption bioavailability.
- This invention is based in part on the use of agents in combination with EDTA that can improve the bioavailability, absorption, and/or half-life of EDTA in the body, thus improving the chances of successful oral administration of EDTA.
- An aspect of the invention relates to novel EDTA-containing compositions, as well as methods of using the compositions. The compositions are useful in therapeutic applications, including modulation of disease or disease symptoms in a patient. The compositions are useful as metal chelators through their ability to bind metals, (e.g., transition state metals).
- According to an aspect of the invention, an orally available composition including piperine and EDTA or a pharmaceutically acceptable derivative or pro-drug thereof is provided. In some instances, the composition also includes a pharmaceutical carrier or an additional therapeutic agent such as an ACE inhibitor, a calcium channel blocker, a beta-blocker, or a diuretic.
- According to another aspect of the invention, an orally available composition including piperine and EDTA is provided.
- According to another aspect of the invention, an orally available composition including enteric coated EDTA or a pharmaceutically acceptable derivative or pro-drug thereof is provided.
- The enteric coating can include cellulose acetate phthalate or hydroxypropylmethylcellulose phthalate. The composition can also include a pharmaceutical carrier or an additional therapeutic agent such as an ACE inhibitor, a calcium channel blocker, a beta-blocker, or a diuretic. In some instances, the additional therupeutic agent is a statin. In some instances, the composition can also include piperine.
- According to another aspect of the invention, an orally available composition including enteric coated EDTA is provided. The composition can also include piperine.
- According to another aspect of the invention, a method for the treatment or prevention of atherosclerosis is provided. The method includes identifying a patient having atherosclerosis or at risk of having atherosclerosis, and orally administering to the patient a composition including EDTA or a pharmaceutically acceptable prodrug or derivative thereof and piperine. In some instances the EDTA is enteric coated. In some instances, the method also includes administering to the patient an additional therapeutic agent such as an ACE inhibitor, a calcium channel blocker, a beta-blocker, or a diuretic. The patient can be identified as having atherosclerosis or being at risk of having atherosclerosis using a calcium score (a measurement obtained by performing an ultrafast electron beam CT scan of the coronary arteries). In some instances the method may also reduce the calcium score.
- According to another aspect of the invention, a method of the treatment or prevention of atherosclerosis is provided that includes identifying a patient having atherosclerosis or at risk for having atherosclerosis, and orally administering to the patient a composition including enteric coated EDTA or a pharmaceutically acceptable prodrug or derivative thereof. In some instances, the composition also includes piperine. In some instances, the method also includes administering to the patient an additional therapeutic agent such as an ACE inhibitor, a calcium channel blocker, a beta-blocker, or a diuretic. The patient can be identified as having atherosclerosis or being at risk of having atherosclerosis using a calcium score. In some instances, the method may reduce the calcium score of the patient.
- Another aspect of the invention includes a method for the treatment of heavy metal accumulation. The method includes identifying a patient having heavy metal accumulation, and orally administering to the patient a composition comprising EDTA or a pharmaceutically acceptable prodrug or derivative thereof and piperine. The composition can be enteric coated. The composition can also be administered together with an additional therapeutic agent.
- Another aspect of the invention includes a method of the treatment heavy metal accumulation, where the method includes identifying a patient having heavy metal accumulation, and orally administering to the patient a composition comprising enteric coated EDTA or a pharmaceutically acceptable prodrug or derivative thereof. In some instances, the composition also includes piperine. In some instances, the method also includes administering to the patient an additional therapeutic agent.
- One or more advantages can be provided from the above. For example, a patient can administer EDTA compositions orally, and need not have them administered intravenously. Accordingly, a patient need not be admitted into a medical facility for treatment, which results in significantly lower costs of administration. In some instances, the compositions disclosed herein require less frequent administration than traditional orally administered EDTA. Moreover, where the EDTA is of a time release formulation, a patient can take higher dosages, as each dose is released in a controlled manner into the blood stream.
- The details of one or more embodiments of the invention are set forth in the description below. Other features, objects, and advantages of the invention will be apparent from the description, and from the claims.
- EDTA binds to metals in the body. Described below are techniques used in the use and preparation of orally available EDTA compositions in patients having atherosclerosis or heavy metal accumulation. The invention also relates to compositions including EDTA related compounds such as cyclohexyl EDTA monoanhydride (CDTAMA) as described in U.S. Pat. No. 5,021,571, or the EDTA related compounds described in U.S. Pat. No. 6,080,785 both of which are incorporated by reference in their entirety.
- There are a variety of methods available to determine the efficacy of the administration of a composition described herein. If the EDTA containing composition is being used to treat heavy metal accumulation, the effectiveness of the composition can be determined, for example, using laboratory tests showing a decrease in amount of toxic heavy metals. On the other hand, if the EDTA containing composition is administered to a patient having coronary artery disease, the effectiveness of the compound can be determined, for example, by the patient's improved performance on a stress test, decrease in chest pain, or decrease in a patient's shortness of breath.
- A possible alternative to monitor the effectiveness of a therapeutic agent in treating coronary artery disease includes the use of coronary artery calcium as a marker for calcified plaque (calcified deposits of cholesterol and fat buildup) in a blood vessel. Plaque formation is also known as atherosclerosis. The presence and amount of calcium detected in a coronary artery by an electron beam computerized tomography (EBCT) scan accurately reflects the presence and amount of calcified atherosclerotic plaque. Coronary artery calcium often occurs years or decades before the development of heart disease symptoms such as chest pain or shortness of breath. Electron beam computerized tomography is a very sensitive method of detecting this calcium, and is therefore a good screening test for coronary atherosclerosis.
- The calcium score for each artery reflects the total amount of calcium in that specific artery of the heart. The total calcium score is equal to the total amount of coronary artery calcium in the heart. Because coronary artery calcium reflects the total amount of calcified plaque in the heart, the higher the calcium scores, the greater the amount of atherosclerosis in the heart. The calcium score does not correlate directly to the percentage narrowing of an artery, but it does correlate with the severity of the underlying coronary atherosclerosis (total plaque burden). However, the higher the calcium score in the heart, the greater the probability of a significant narrowing of arteries throughout the patient.
- The calcium score is used to determine the calcium percentile, which compares the patient's calcium score to that of other asymptomatic or symptomatic people of the same age and sex. The calcium score, in combination with the calcium percentile, enables a physician to determine the risk to a patient of developing symptomatic coronary artery disease, and to measure the progression of disease and the effectiveness of treatment. Table 1 below provides an example of a correlation of calcium scores to risk of Coronary Artery Disease (CAD).
TABLE 1 Calcium Scores and correlation to CAD EBCT Calcium Probability of Score Plaque Burden Significant CAD 0 No identifiable Very low (generally plaque burden <5% likelihood) 0-10 Minimal identifiable Very unlikely plaque burden (generally <10% likelihood) 11-100 Definite (at least Mild or minimal mild) coronary stenoses likely 101-400 Definite (at least Nonobstructive moderate CAD highly likely, atherosclerotic although obstructive plaque burden) disease possible >400 Extensive High likelihood (>90%) of at least one “significant” coronary stenosis
Administering EDTA compositions to a patient may improve that patient's calcium score. - Disclosed are techniques for improving the effectiveness of EDTA administered orally. One approach combines EDTA with a bioavailability enhancer such as piperine. The resulting composition can improve absorption of the EDTA into the bloodstream, relative to the administration of EDTA alone. The combination of piperine with EDTA and EDTA related compounds could result in a higher plasma concentration and a longer presence of the EDTA in the body, thus improving the effectiveness of the EDTA or related compound. Accordingly, this can allow a smaller dose to be used (correlating to the increased effectiveness). The decrease in dose can correlate with decreased side effects (i.e., reduced toxicity) of the EDTA.
- The effective bioenhancing dose of piperine for EDTA compounds can vary, however a dose of approximately 0.2-5% (wt/wt) (e.g., 0.25, 0.5, 1.0, 2.0, 4.0, 5.0% wt/wt or any range in between) of the active drug (e.g., EDTA) can be an appropriate bioenhancing dose of piperine to improve the bioavailability of the EDTA.
- There are two plausible explanations of the role that piperine may have in improving the bioavailability of EDTA and related compounds: a) non-specific mechanisms promoting rapid absorption of drugs and nutrients, e.g., increased blood supply to the gastrointestinal tract, decreased hydrochloric acid secretion which prevents breakdown of some drugs, increased emulsifying content of the gut, increased enzymes like gamma-glutamyl transpeptidase which participate in active and passive transport of nutrients to the intestinal cells, and b) non-specific mechanisms inhibiting enzymes participating in biotransformation of drugs, preventing their inactivation and elimination.
- The improved bioavailability with administration of piperine can be a result of both of the mechanisms, i.e., increased absorption from the gut and the slow down of biotransformation, inactivation and elimination from the system. The latter mechanism is probably the most important in sustaining the elevated blood levels of the EDTA, and making it more bioavailable to the tissue. Although a rapid absorption to the blood stream may account for increased blood levels of the EDTA, it is the inhibition of drug (i.e., EDTA) biotransforming enzymes with piperine that makes a drug stay in the body longer, in higher quantities, which makes it more effective.
- EDTA and/or related compounds can also have an enteric coating to prevent degradation of the compound in the stomach. An enteric coating does not dissolve in the acidic environment of the stomach, but rather dissolves in the alkaline environment of the small intestine. Accordingly, the drug (e.g., EDTA or a related compound) is able to pass through the stomach and is released from the small intestine, which provides improved bioavailability. Methods of enteric coating are known to those of skill in the art as seen for example in C. Signorino, “Aqueous Enteric Coating,” Pharm. Technol. Tableting & Granulation Yearbook 25-26 (1999) and M. P. Jordan et al, “A Comparison of the Performance Characteristics of Enteric Film Coating Systems,” AAPS National Meeting (October 1999). Many examples of compounds used for enteric coating are known in the art, for example Eudragit-L-100 NF can be used as an enteric coating.
- Another aspect of this formulation is that the EDTA is in a “time-release” formulation. One advantage of a time release formulation is that the time-release provides a more even amount of active drug (e.g., EDTA) in the blood stream over a prolonged period of time, thus reducing or in some instances avoiding the frequent peaks and valleys of medication levels one can encounter using more traditional methods of oral administration. Accordingly, the patient is provided with a more stable therapeutic environment. Another advantage of the time release formulation is that it allows the patient to take dosages of the EDTA or EDTA related compound with less frequency than would be required with uncoated EDTA. Examples of time release formulations include cocoa butter, waxes, polymers, etc. Another example of a time release formulation is methylcellulose K 100 M USP. Formulations that release the desired compound over about 6 to about 8 hours are generally preferred.
- The term “bioavailability” refers to the degree and rate at which a substance (e.g., a drug) is absorbed into a living system or is made available at the site of physiological activity.
- The term “diuretic” refers to a substance, which increases the production and elimination of urine.
- The term “beta-blocker” refers to a pharmaceutical agent, such as propanolol, that opposes the excitatory effects of norepinephrine released from sympathetic nerve endings at beta-receptors and is used for the treatment of angina, hypertension, arrhythmia, and migraine. Also called beta-adrenergic blocking agent.
- The term “ACE inhibitor” refers to an antihypertensive drug that blocks the formation of angiotensin in the kidney, leading to relaxation of the arteries and promotes the excretion of salt and water by inhibiting the activity of the angiotensin converting enzyme.
- The term “calcium channel blocker” refers to a pharmaceutical agent that prevents or slows the influx of calcium ions into smooth muscle cells. Calcium channel blockers can be used, for example, to treat some forms of angina pectoris and some cardiac arrhythmias.
- The term “statin” refers to of pharmaceutical agent that acts by competitively inhibiting 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, an enzyme involved in the liver cholesterol synthesis.
- A “pharmaceutically acceptable derivative or prodrug” means any pharmaceutically acceptable salt, ester, salt of an ester, or other derivative of a compound of this invention, which, upon administration to a recipient, is capable of providing (directly or indirectly) a compound of this invention. Particularly favored derivatives and prodrugs are those that increase the bioavailability of the compounds of this invention when such compounds are administered to a mammal (e.g., by allowing an orally administered compound to be more readily absorbed into the blood) or which enhance delivery of the parent compound to a biological compartment (e.g., the brain or lymphatic system) relative to the parent species. Preferred prodrugs include derivatives where a group which enhances aqueous solubility or active transport through the gut membrane is appended to the structure of formulae described herein.
- The compounds of this invention (e.g., EDTA and EDTA related compounds) may be modified by appending appropriate chemical functionalities (e.g., carboxylic acids, esters, amides, ethers, etc.) to enhance selective biological properties. Such modifications are known in the art and include those which increase biological penetration into a given biological compartment (e.g., blood, lymphatic system, central nervous system), increase oral availability, increase solubility to allow administration by injection, alter metabolism and alter rate of excretion.
- Pharmaceutically acceptable salts of the compounds of this invention include those derived from pharmaceutically acceptable inorganic and organic acids and bases. Examples of suitable acid salts include acetate, adipate, benzoate, benzenesulfonate, butyrate, citrate, digluconate, dodecylsulfate, formate, fumarate, glycolate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, lactate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, palmoate, phosphate, picrate, pivalate, propionate, salicylate, succinate, sulfate, tartrate, tosylate and undecanoate. Salts derived from appropriate bases include alkali metal (e.g., sodium), alkaline earth metal (e.g., magnesium), ammonium and N-(alkyl)4 + salts. This invention also envisions the quaternization of any basic nitrogen-containing groups of the compounds disclosed herein. Water or oil-soluble or dispersible products may be obtained by such quaternization.
- The methods herein contemplate administration of an effective amount of compound or compound composition to achieve the desired or stated effect. Typically, the compositions of this invention will be administered from about 1 to about 6 times per day. Each dose (i.e., administration) can be about 250-1500 mg EDTA or pharmaceutically acceptable derivative or prodrug thereof, (e.g., 100-750 mg., 150-600 mg., 200-400 mg., or about 250 mg). Such administration can be used as a chronic, acute, or prophylactic therapy. The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the patient treated. A typical preparation will contain from about 5% to about 95% active compound (wt/wt) Alternatively, such preparations contain from about 20% to about 80% active compound.
- Where EDTA or an EDTA related compound is administered together with piperine, the piperine is administered at about 0.2-5% (wt/wt) (e.g., 0.2-1.0, 1.0-2.5, or 2.5-5% wt/wt) relative to the EDTA or related compound.
- Lower or higher doses than those recited above may be required. Specific dosage and treatment regimens for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health status, sex, diet, time of administration, rate of excretion, drug combination, the severity and course of the disease, condition or symptoms, the patient's disposition to the disease, condition or symptoms, and the judgment of the treating physician.
- Upon improvement of a patient's condition, a maintenance dose of a composition of this invention can be administered, if necessary. Subsequently, the dosage or frequency of administration, or both, may be reduced, as a function of the symptoms, to a level at which the improved condition is retained. Patients may, however, require intermittent treatment on a long-term basis upon any recurrence of disease symptoms.
- Compositions of this invention can include EDTA or a pharmaceutically acceptable derivative or prodrug thereof; an additional agent including for example, piperine, acebutolol, bisoprololm, captopril, enalapril, hydrochlorothiazide, etc; and any pharmaceutically acceptable carrier, adjuvant or vehicle. Alternate compositions of this invention include EDTA or a pharmaceutically acceptable derivative or prodrug thereof; and a pharmaceutically acceptable carrier, adjuvant or vehicle. The compositions delineated herein include EDTA and derivatives thereof, as well as additional therapeutic agents if present, in amounts effective for achieving a modulation of disease or disease symptoms, including atherosclerosis or symptoms thereof.
- The term “pharmaceutically acceptable carrier or adjuvant” refers to a carrier or adjuvant that may be administered to a patient, together with a compound of this invention, and which does not destroy the pharmacological activity thereof and is nontoxic when administered in doses sufficient to deliver a therapeutic amount of the compound.
- Pharmaceutically acceptable carriers, adjuvants and vehicles that may be used in the pharmaceutical compositions of this invention include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, self-emulsifying drug delivery systems (SEDDS) such as d-α-tocopherol polyethyleneglycol 1000 succinate, surfactants used in pharmaceutical dosage forms such as Tweens or other similar polymeric delivery matrices, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat. Cyclodextrins such as α-, β-, and γ-cyclodextrin, may also be advantageously used to enhance delivery of compounds of the formulae described herein.
- The pharmaceutical compositions of this invention can be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, emulsions and aqueous suspensions, dispersions and solutions. In the case of tablets for oral use, carriers that are commonly used include lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a capsule form, useful diluents include lactose and dried corn starch. When aqueous suspensions and/or emulsions are administered orally, the active ingredient may be suspended or dissolved in an oily phase is combined with emulsifying and/or suspending agents. If desired, certain sweetening and/or flavoring and/or coloring agents may be added.
- When the compositions of this invention include a combination of EDTA or a pharmaceutically acceptable prodrug or derivative thereof and one or more additional therapeutic or agents, both the compound and the additional agent should be present at dosage levels of between about 1 to 100%, and e.g., between about 5 to 95% of the dosage normally administered in a monotherapy regimen. The additional agents may be administered separately, as part of a multiple dose regimen, from the compounds of this invention. Alternatively, those agents may be part of a single dosage form, mixed together with the compounds of this invention in a single composition.
- The compounds, compositions, and methods of combination therapy delineated herein are useful to treat atherosclerosis and related symptoms. The concept of “treating” or “treatment” refers to activity that prevents, alleviates, or ameliorates any primary phenomena or secondary symptoms associated with atherosclerosis or heavy metal accumulation.
- A number of embodiments of the invention have been described. Nevertheless, it will be understood that various modifications may be made without departing from the spirit and scope of the invention. Accordingly, other embodiments are within the scope of the following claims.
Claims (33)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/939,737 US8685374B2 (en) | 2003-09-12 | 2004-09-13 | EDTA containing compositions and uses thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50282003P | 2003-09-12 | 2003-09-12 | |
US10/939,737 US8685374B2 (en) | 2003-09-12 | 2004-09-13 | EDTA containing compositions and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
US20050112200A1 true US20050112200A1 (en) | 2005-05-26 |
US8685374B2 US8685374B2 (en) | 2014-04-01 |
Family
ID=34375287
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/939,737 Active 2032-12-10 US8685374B2 (en) | 2003-09-12 | 2004-09-13 | EDTA containing compositions and uses thereof |
Country Status (2)
Country | Link |
---|---|
US (1) | US8685374B2 (en) |
WO (1) | WO2005027832A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060035975A1 (en) * | 2004-02-26 | 2006-02-16 | Keith Alec D | Enteric coated oral pharmaceutical to erode kidney stones |
US20090202516A1 (en) * | 2008-02-08 | 2009-08-13 | Prothera, Inc. | Inhibition and treatment of gastrointestinal biofilms |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006117660A2 (en) * | 2005-05-04 | 2006-11-09 | Clio Pharmaceutical Corporation | Method for treating cancer, coronary, inflammatory and macular disease, combining the modulation of zinc- and/or copper dependent proteins |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3838196A (en) * | 1972-09-25 | 1974-09-24 | J Mercer | Method of treating arteriosclerosis |
US5536506A (en) * | 1995-02-24 | 1996-07-16 | Sabinsa Corporation | Use of piperine to increase the bioavailability of nutritional compounds |
US20020169192A1 (en) * | 2001-02-15 | 2002-11-14 | Hayward Cheryl M. | PPAR compounds |
US6645510B1 (en) * | 1998-06-30 | 2003-11-11 | American Medical Research, Inc. | Method of treating topical ailments |
US20040009896A1 (en) * | 2002-05-24 | 2004-01-15 | Peter Glynn | Oral lactoferrin in the treatment of respiratory disorders |
US20050261257A1 (en) * | 2002-08-30 | 2005-11-24 | Vitak Bv | Compositions for treating or preventing cardiovascular disease |
-
2004
- 2004-09-13 US US10/939,737 patent/US8685374B2/en active Active
- 2004-09-13 WO PCT/US2004/029664 patent/WO2005027832A2/en active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3838196A (en) * | 1972-09-25 | 1974-09-24 | J Mercer | Method of treating arteriosclerosis |
US5536506A (en) * | 1995-02-24 | 1996-07-16 | Sabinsa Corporation | Use of piperine to increase the bioavailability of nutritional compounds |
US6645510B1 (en) * | 1998-06-30 | 2003-11-11 | American Medical Research, Inc. | Method of treating topical ailments |
US20020169192A1 (en) * | 2001-02-15 | 2002-11-14 | Hayward Cheryl M. | PPAR compounds |
US20040009896A1 (en) * | 2002-05-24 | 2004-01-15 | Peter Glynn | Oral lactoferrin in the treatment of respiratory disorders |
US20050261257A1 (en) * | 2002-08-30 | 2005-11-24 | Vitak Bv | Compositions for treating or preventing cardiovascular disease |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060035975A1 (en) * | 2004-02-26 | 2006-02-16 | Keith Alec D | Enteric coated oral pharmaceutical to erode kidney stones |
US7563460B2 (en) * | 2004-02-26 | 2009-07-21 | Med Five, Inc. | Enteric coated oral pharmaceutical to erode kidney stones |
US20090202516A1 (en) * | 2008-02-08 | 2009-08-13 | Prothera, Inc. | Inhibition and treatment of gastrointestinal biofilms |
US11078516B2 (en) | 2008-02-08 | 2021-08-03 | Prothera, Inc. | Inhibition and treatment of gastrointestinal biofilms |
Also Published As
Publication number | Publication date |
---|---|
WO2005027832A2 (en) | 2005-03-31 |
US8685374B2 (en) | 2014-04-01 |
WO2005027832A3 (en) | 2005-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1003503B1 (en) | Therapeutic combinations comprising amlodipin and atorvastatin | |
EP1009400B1 (en) | Combination therapy comprising atorvastatin and an antihypertensive agent | |
JP2001514224A (en) | Combination therapy including amlodipine and statin compound | |
KR20020019450A (en) | Mutual salt of amlodipine and atorvastatin | |
KR101502031B1 (en) | Pharmaceutical combination preparation | |
US20070149578A1 (en) | Combination Therapy | |
JP2002508320A (en) | Statin-carboxyalkyl ether formulation | |
US8685374B2 (en) | EDTA containing compositions and uses thereof | |
US6737430B2 (en) | Mutual prodrug of amlodipine and atorvastatin | |
EA006776B1 (en) | Medical composition for treating diabetic neuropathy | |
KR20020091245A (en) | Antihypertensive Agents and Use | |
US20240115572A1 (en) | Methods for treating glioblastomas with sepiapterin | |
US20110269786A1 (en) | Treatment of major adverse cardiac events and acute coronary syndrome in diabetic patients using secretory phospholipase a2 (spla2) inhibitor or spla2 inhibitor combination therapies | |
JP2024508686A (en) | Fospropofol methods and compositions | |
KR20230000506A (en) | Pharmaceutical combination preparation comprising candesartan, amlodipine and atorvastatin | |
UA146871U (en) | PHARMACEUTICAL COMPOSITION | |
EP1205477A1 (en) | Mutual prodrug of amlodipine and atorvastatin | |
van den Ouweland et al. | Abstracts of papers clinical pharmacological meeting | |
SA98190566B1 (en) | Combinations include amlodipine and atorvastatin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: RAY AND TERRY'S HEALTH PRODUCTS, INC., MASSACHUSET Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GROSSMAN, TERRY;KURZWEIL, RAYMOND C.;REEL/FRAME:016205/0689;SIGNING DATES FROM 20050107 TO 20050124 Owner name: RAY AND TERRY'S HEALTH PRODUCTS, INC., MASSACHUSET Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GROSSMAN, TERRY;KURZWEIL, RAYMOND C.;SIGNING DATES FROM 20050107 TO 20050124;REEL/FRAME:016205/0689 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2551) Year of fee payment: 4 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2552); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY Year of fee payment: 8 |